Astria Therapeutics (ATXS) Operating Income: 2013-2018
Historic Operating Income for Astria Therapeutics (ATXS) over the last 6 years, with Dec 2018 value amounting to -$26.4 million.
- Astria Therapeutics' Operating Income fell 10.75% to -$6.1 million in Q4 2018 from the same period last year, while for Dec 2018 it was -$26.4 million, marking a year-over-year increase of 2.79%. This contributed to the annual value of -$26.4 million for FY2018, which is 2.67% up from last year.
- Per Astria Therapeutics' latest filing, its Operating Income stood at -$26.4 million for FY2018, which was up 2.67% from -$27.1 million recorded in FY2017.
- In the past 5 years, Astria Therapeutics' Operating Income ranged from a high of -$21.7 million in FY2014 and a low of -$35.6 million during FY2016.
- In the last 3 years, Astria Therapeutics' Operating Income had a median value of -$27.1 million in 2017 and averaged -$29.7 million.
- In the last 5 years, Astria Therapeutics' Operating Income plummeted by 46.02% in 2015 and then grew by 23.80% in 2017.
- Over the past 5 years, Astria Therapeutics' Operating Income (Yearly) stood at -$21.7 million in 2014, then tumbled by 46.02% to -$31.7 million in 2015, then dropped by 12.32% to -$35.6 million in 2016, then increased by 23.80% to -$27.1 million in 2017, then increased by 2.67% to -$26.4 million in 2018.